Cost-utility analysis of empagliflozin on chronic kidney disease progression in Thailand
At the current willingness-to-pay threshold of 160,000 THB/QALY, empagliflozin was cost-effective for treating patients with CKD without or with DM.
Authors
- Bancha Satirapoj (ORCID: https://orcid.org/0000-0002-8881-0942)
- Piyameth Dilokthornsakul (ORCID: https://orcid.org/0000-0002-6981-1771)
- Vuddhidej Ophascharoensuk (ORCID: https://orcid.org/0000-0002-6041-7989)
- Wanchana Singhan (ORCID: https://orcid.org/0000-0002-3158-4673)
- Paweena Susantitaphong
Institutions
- Chulalongkorn University (TH)
- King Chulalongkorn Memorial Hospital (TH)
- Phramongkutklao Hospital (TH)
- Chiang Mai University (TH)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1080/13696998.2025.2474887
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29